Compare ZIM & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZIM | QURE |
|---|---|---|
| Founded | 1945 | 1998 |
| Country | Israel | Netherlands |
| Employees | N/A | 248 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | 2020 | 2013 |
| Metric | ZIM | QURE |
|---|---|---|
| Price | $29.77 | $20.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $29.18 | ★ $58.12 |
| AVG Volume (30 Days) | 1.0M | ★ 1.6M |
| Earning Date | 11-18-2026 | 11-04-2026 |
| Dividend Yield | ★ 8.96% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $17.31 | $39.49 |
| Revenue Next Year | N/A | $402.79 |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.45 | $8.73 |
| 52 Week High | $30.98 | $51.72 |
| Indicator | ZIM | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 33.98 |
| Support Level | $27.18 | $13.96 |
| Resistance Level | $29.70 | $26.07 |
| Average True Range (ATR) | 0.82 | 1.81 |
| MACD | 0.15 | 0.06 |
| Stochastic Oscillator | 65.06 | 1.20 |
ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.